Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 70,000 shares at $49.02 ($3.4M) on 2013-02-21, disclosed to the SEC on 2013-02-22.
Scheduled sale ($3.4M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.49 | 18,654 | $923K | 26.8% |
| 2 | $49.60 | 5,954 | $295K | 8.6% |
| 3 | $49.02 | 45,392 | $2.2M | 64.6% |
| Total | $49.19 avg | 70,000 | $3.4M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |